Greg Lucier, chairman, president, and CEO of Invitrogen, will become CEO of Applied Biosystems following Invitrogen’s planned acquisition of the company.  
Mark Stevenson, president and chief operating officer of ABI, will retain that role in the new company.
David Hoffmeister, senior vice president of finance and chief financial officer of Invitrogen, will remain CFO of the new ABI.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.